# Trupanion, Inc.: overview

TRUP · Nasdaq · CIK 1371285 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/trup.md) · [Financials](/companies/trup/financials.md) · [Filings](/companies/trup/filings.md) · [Insiders](/companies/trup/insiders.md)

Latest reported revenue: [$392.9m](/filings/0001371285-26-000172.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 5, 2026 (XBRL us-gaap:Revenues, accession 0001371285-26-000172).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [327](/filings/0001371285-25-000250.md) | [337 d](/filings/0001371285-26-000018.md) | [342](/filings/0001371285-26-000096.md) | [354](/filings/0001371285-26-000172.md) | [367](/filings/0001371285-25-000250.md) | [377 d](/filings/0001371285-26-000018.md) | [384](/filings/0001371285-26-000096.md) | [393](/filings/0001371285-26-000172.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [0.5%](/filings/0001371285-25-000250.md) | [0.1% d](/filings/0001371285-26-000018.md) | [(0.4%)](/filings/0001371285-26-000096.md) | [0.7%](/filings/0001371285-26-000172.md) | [1.6%](/filings/0001371285-25-000250.md) | [1.9% d](/filings/0001371285-26-000018.md) | [1.2%](/filings/0001371285-26-000096.md) | [1.6%](/filings/0001371285-26-000172.md) |
| Net margin | % | [0.4%](/filings/0001371285-25-000250.md) | [0.5% d](/filings/0001371285-26-000018.md) | [(0.4%)](/filings/0001371285-26-000096.md) | [2.7%](/filings/0001371285-26-000172.md) | [1.6%](/filings/0001371285-25-000250.md) | [1.5% d](/filings/0001371285-26-000018.md) | [1.3%](/filings/0001371285-26-000096.md) | [1.7%](/filings/0001371285-26-000172.md) |
| Diluted EPS | $ per share | [0.03](/filings/0001371285-25-000250.md) | not reported | [(0.03)](/filings/0001371285-26-000096.md) | [0.22](/filings/0001371285-26-000172.md) | [0.13](/filings/0001371285-25-000250.md) | not reported | [0.11](/filings/0001371285-26-000096.md) | [0.16](/filings/0001371285-26-000172.md) |
| Free cash flow | $m | [13.4 d](/filings/0001371285-25-000250.md) | [21.8 d](/filings/0001371285-26-000018.md) | [14.0](/filings/0001371285-26-000096.md) | [12.0 d](/filings/0001371285-26-000172.md) | [23.9 d](/filings/0001371285-25-000250.md) | [25.3 d](/filings/0001371285-26-000018.md) | [13.7](/filings/0001371285-26-000096.md) | [19.2 d](/filings/0001371285-26-000172.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [699](/filings/0001371285-24-000029.md) | [905](/filings/0001371285-25-000052.md) | [1,109](/filings/0001371285-26-000018.md) | [1,286](/filings/0001371285-26-000018.md) | [1,439](/filings/0001371285-26-000018.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(5.0%)](/filings/0001371285-24-000029.md) | [(4.8%)](/filings/0001371285-25-000052.md) | [(3.7%)](/filings/0001371285-26-000018.md) | [(0.7%)](/filings/0001371285-26-000018.md) | [1.0%](/filings/0001371285-26-000018.md) |
| Net margin | % | [(5.1%)](/filings/0001371285-24-000029.md) | [(4.9%)](/filings/0001371285-25-000052.md) | [(4.0%)](/filings/0001371285-26-000018.md) | [(0.7%)](/filings/0001371285-26-000018.md) | [1.4%](/filings/0001371285-26-000018.md) |
| Diluted EPS | $ per share | [(0.89)](/filings/0001371285-24-000029.md) | [(1.10)](/filings/0001371285-25-000052.md) | [(1.08)](/filings/0001371285-26-000018.md) | [(0.23)](/filings/0001371285-26-000018.md) | [0.45](/filings/0001371285-26-000018.md) |
| Free cash flow | $m | [(4.9)](/filings/0001371285-24-000029.md) | [(25.1)](/filings/0001371285-25-000052.md) | [0.4](/filings/0001371285-26-000018.md) | [38.6](/filings/0001371285-26-000018.md) | [75.4](/filings/0001371285-26-000018.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/trup/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $134.8m | 5,441,008 |  | Reduced −2,112 |
| [Capital World Investors](/funds/1422849.md) | 2026-06-30 | $95.1m | 3,840,269 |  | Added +58,630 |
| [Aflac Inc](/funds/4977.md) | 2026-06-30 | $90.1m | 3,636,364 |  | Unchanged |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $44.6m | 1,801,498 |  | Added +38,921 |
| [Polar Capital Holdings Plc](/funds/1837309.md) | 2026-06-30 | $43.3m | 1,750,000 |  | Added +125,000 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $36.8m | 1,486,377 |  | Added +33,221 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $33.8m | 1,365,662 |  | Added +48,219 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $25.8m | 1,040,565 |  | Reduced −314,001 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $22.3m | 901,215 |  | Added +203,343 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $21.7m | 875,839 |  | Reduced −2,231 |

## Recent filings

[All 1,598 filings](/companies/trup/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-05 | 21:02 ET | [10-Q](/filings/0001371285-26-000172.md) | Quarterly report, period 2026-06-30 | 0001371285-26-000172 |
| 2026-08-05 | 20:03 ET | [8-K](/filings/0001371285-26-000171.md) | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001371285-26-000171 |
| 2026-06-15 | 20:04 ET | [8-K](/filings/0001371285-26-000155.md) | 5.07 Shareholder vote results | 0001371285-26-000155 |
| 2026-04-30 | 20:12 ET | [8-K](/filings/0001371285-26-000098.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001371285-26-000098 |
| 2026-04-30 | 20:04 ET | [10-Q](/filings/0001371285-26-000096.md) | Quarterly report, period 2026-03-31 | 0001371285-26-000096 |
| 2026-04-27 | 20:18 ET | [8-K](/filings/0001371285-26-000083.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure | 0001371285-26-000083 |
| 2026-04-27 | 20:05 ET | [DEF 14A](/filings/0001371285-26-000081.md) | Proxy statement, period 2025-12-31 | 0001371285-26-000081 |
| 2026-02-13 | 21:07 ET | [10-K](/filings/0001371285-26-000018.md) | Annual report, period 2025-12-31 | 0001371285-26-000018 |
| 2026-02-12 | 21:01 ET | [8-K](/filings/0001371285-26-000008.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001371285-26-000008 |
| 2025-11-06 | 22:02 ET | [10-Q](/filings/0001371285-25-000250.md) | Quarterly report, period 2025-09-30 | 0001371285-25-000250 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001371285-26-000018.md), filed Feb 13, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/5243f87a-e429-45d5-80bc-de7cedf9e223)

## About the filer

- CIK: 1371285
- Tickers: TRUP
- Exchange: Nasdaq
- SIC code: 6324 Hospital & Medical Service Plans
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.